Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset

European Journal of Immunology

Volumn 46, Issue 4, 2016, Pages 1030-1046

  Cabrera, Susanne M ^a   Wang, Xujing ^b   Chen, Yi Guang ^a   Jia, Shuang ^a   Kaldunski, Mary L ^a   Greenbaum, Carla J ^c   Mandrup Poulsen, Thomas ^d,e   Hessner, Martin J ^a  

^a Children's Hospital and Health Systems   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c BENAROYA RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Anakinra; Canakinumab; Interleukin 1; Transcriptional signatures; Type 1 diabetes

Indexed keywords

C PEPTIDE; CANAKINUMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; IL1A PROTEIN, HUMAN; IL1B PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ARTICLE; CONTROLLED STUDY; GENE ONTOLOGY; HUMAN; HUMAN CELL; IMMUNOMODULATION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BLOCKING; TREATMENT RESPONSE; ADULT; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 1; IMMUNOLOGY; IMMUNOTHERAPY; PHYSIOLOGY; PROCEDURES;

ADULT; ANTIBODIES, MONOCLONAL; CELLS, CULTURED; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNOTHERAPY; INFLAMMATION; INSULIN-SECRETING CELLS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; MALE;

EID: 84955291992     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201546005     Document Type: Article

References (38)

1. Mandrup-Poulsen, T., Pickersgill, L. and Donath, M. Y., Blockade of interleukin 1 in type 1 diabetes mellitus. Nat. Rev. Endocrinol. 2010. 6: 158-166.
2. Todd, J. A., Etiology of type 1 diabetes. Immunity 2010. 32: 457-467.
3. Stiller, C. R., Dupre, J., Gent, M., Jenner, M. R., Keown, P. A., Laupacis, A., Martell, R. et al., Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 1984. 223: 1362-1367.
4. Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, L., Hale, G., Gorus, F. et al., Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 2005. 352: 2598-2608.
5. Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A. et al., Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N. Engl. J. Med. 2009. 361: 2143-2152.
6. Sandler, S., Andersson, A. and Hellerstrom, C., Inhibitory effects of interleukin 1 on insulin secretion, insulin biosynthesis, and oxidative metabolism of isolated rat pancreatic islets. Endocrinology 1987. 121: 1424-1431.
7. Spinas, G. A., Hansen, B. S., Linde, S., Kastern, W., Molvig, J., Mandrup-Poulsen, T., Dinarello, C. A. et al., Interleukin 1 dose-dependently affects the biosynthesis of (pro)insulin in isolated rat islets of Langerhans. Diabetologia 1987. 30: 474-480.
8. Mandrup-Poulsen, T., Bendtzen, K., Nerup, J., Dinarello, C. A., Svenson, M. and Nielsen, J. H., Affinity-purified human interleukin I is cytotoxic to isolated islets of Langerhans. Diabetologia 1986. 29: 63-67.
9. Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N. et al., Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J. Clin. Invest. 2002. 110: 851-860.
10. Yamada, K., Takane-Gyotoku, N., Yuan, X., Ichikawa, F., Inada, C. and Nonaka, K., Mouse islet cell lysis mediated by interleukin-1-induced Fas. Diabetologia 1996. 39: 1306-1312.
11. Dayer-Metroz, M. D., Wollheim, C. B., Seckinger, P. and Dayer, J. M., A natural interleukin 1 (IL-1) inhibitor counteracts the inhibitory effect of IL-1 on insulin production in cultured rat pancreatic islets. J. Autoimmun. 1989. 2: 163-171.
12. Zumsteg, U., Reimers, J. I., Pociot, F., Morch, L., Helqvist, S., Brendel, M., Alejandro, R. et al., Differential interleukin-1 receptor antagonism on pancreatic beta and alpha cells. Studies in rodent and human islets and in normal rats. Diabetologia 1993. 36: 759-766.
13. Dinarello, C. A., Simon, A. and van der Meer, J. W., Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat. Rev. Drug Discov. 2012. 11: 633-652.
14. Kaldunski, M., Jia, S., Geoffrey, R., Basken, J., Prosser, S., Kansra, S., Mordes, J. P. et al., Identification of a serum-induced transcriptional signature associated with type 1 diabetes in the BioBreeding rat. Diabetes 2010. 59: 2375-2385.
15. Dayer-Metroz, M.-D., Duhamel, D., Rufer, N., Izui, S., Carmichaels, D., Wollheim, C. B., Thompson, R. C. and Dayer, J.-M., IL-1 receptor antagonist delays spontaneous autoimmune diabetes in BB rats. Eur. J. Clin. Invest. 1992. 22: Abstract 285.
16. Nicoletti, F., Di Marco, R., Barcellini, W., Magro, G., Schorlemmer, H. U., Kurrle, R., Lunetta, M. et al., Protection from experimental autoimmune diabetes in the non-obese diabetic mouse with soluble interleukin-1 receptor. Eur. J. Immunol. 1994. 24: 1843-1847.
17. Hara, N., Alkanani, A. K., Dinarello, C. A. and Zipris, D., Modulation of virus-induced innate immunity and type 1 diabetes by IL-1 blockade. Innate Immun. 2013. 20: 574-584.
18. Larsen, C. M., Faulenbach, M., Vaag, A., Volund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T. and Donath, M. Y., Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 2007. 356: 1517-1526.
19. Cavelti-Weder, C., Babians-Brunner, A., Keller, C., Stahel, M. A., Kurz-Levin, M., Zayed, H., Solinger, A. M. et al., Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 2012. 35: 1654-1662.
20. Moran, A., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Greenbaum, C. J. et al., Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 2013. 381: 1905-1915.
21. Wang, X., Jia, S., Geoffrey, R., Alemzadeh, R., Ghosh, S. and Hessner, M. J., Identification of a molecular signature in human type 1 diabetes mellitus using serum and functional genomics. J. Immunol. 2008. 180: 1929-1937.
22. Levy, H., Wang, X., Kaldunski, M., Jia, S., Kramer, J., Pavletich, S. J., Reske, M. et al., Transcriptional signatures as a disease-specific and predictive inflammatory biomarker for type 1 diabetes. Genes Immun. 2012. 13: 593-604.
23. Chen, Y. G., Cabrera, S. M., Jia, S., Kaldunski, M. L., Kramer, J., Cheong, S., Geoffrey, R. et al., Molecular signatures differentiate immune States in type 1 diabetic families. Diabetes 2014. 63: 3960-3973.
24. Liu, J., Zhang, H., Liu, Y., Wang, K., Feng, Y., Liu, M. and Xiao, X., KLF4 regulates the expression of interleukin-10 in RAW264.7 macrophages. Biochem. Biophys. Res. Commun. 2007. 362: 575-581.
25. Peter, M. R., Jerkic, M., Sotov, V., Douda, D. N., Ardelean, D. S., Ghamami, N., Lakschevitz, F. et al., Impaired resolution of inflammation in the Endoglin heterozygous mouse model of chronic colitis. Mediators Inflamm. 2014. 2014: 767185.
26. Ablamunits, V., Henegariu, O., Hansen, J. B., Opare-Addo, L., Preston-Hurlburt, P., Santamaria, P., Mandrup-Poulsen, T. and Herold, K. C., Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation. Diabetes 2012. 61: 145-154.
27. Pagni, P. P., Bresson, D., Rodriguez-Calvo, T., Bel Hani, A., Manenkova, Y., Amirian, N., Blaszczak, A. et al., Combination therapy with an anti-IL-1beta antibody and GAD65 DNA vaccine can reverse recent-onset diabetes in the RIP-GP mouse model. Diabetes 2014. 63: 2015-2025.
28. Hussain, M. J., Peakman, M., Gallati, H., Lo, S. S., Hawa, M., Viberti, G. C., Watkins, P. J. et al., Elevated serum levels of macrophage-derived cytokines precede and accompany the onset of IDDM. Diabetologia 1996. 39: 60-69.
29. Dogan, Y., Akarsu, S., Ustundag, B., Yilmaz, E. and Gurgoze, M. K., Serum IL-1beta, IL-2, and IL-6 in insulin-dependent diabetic children. Mediators Inflamm. 2006. 2006: 59206.
30. Crino, A., Schiaffini, R., Manfrini, S., Mesturino, C., Visalli, N., Beretta Anguissola, G., Suraci, C. et al., A randomized trial of nicotinamide and vitamin E in children with recent onset type 1 diabetes (IMDIAB IX). Eur. J. Endocrinol. 2004. 150: 719-724.
31. Greenbaum, C. J., Beam, C. A., Boulware, D., Gitelman, S. E., Gottlieb, P. A., Herold, K. C., Lachin, J. M. et al., Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 2012. 61: 2066-2073.
32. Sherry, N., Hagopian, W., Ludvigsson, J., Jain, S. M., Wahlen, J., Ferry, R. J., Jr., Bode, B. et al., Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011. 378: 487-497.
33. Gentleman, R. C., Carey, V. J., Bates, D. M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B. et al., Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004. 5: R80.
34. Huang da, W., Sherman, B. T. and Lempicki, R. A., Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009. 4: 44-57.
35. Sturn, A., Quackenbush, J. and Trajanoski, Z., Genesis: cluster analysis of microarray data. Bioinformatics 2002. 18: 207-208.
36. Edgar, R., Domrachev, M. and Lash, A. E., Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002. 30: 207-210.
37. Orjalo, A. V., Bhaumik, D., Gengler, B. K., Scott, G. K. and Campisi, J., Cell surface-bound IL-1alpha is an upstream regulator of the senescence-associated IL-6/IL-8 cytokine network. Proc. Natl. Acad. Sci. USA 2009. 106: 17031-17036.
38. Olaru, F. and Jensen, L. E., Staphylococcus aureus stimulates neutrophil targeting chemokine expression in keratinocytes through an autocrine IL-1alpha signaling loop. J. Invest. Dermatol. 2010. 130: 1866-1876.